Midazolam: 9 agencies, 2003–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 22.2 years separate the first record, 23 Jul 2003 at HAS (France), from the most recent, 2 Sep 2025 at HAS (France).
CIPM (Spain) changed its position: not recommended on 12 Nov 2020, recommended by 16 Jul 2025, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
The file is active: 11 of 30 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for midazolam by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 30 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess midazolam, on 23 Jul 2003; AOTMIT (Poland) did not open a file until 31 Jul 2025 — an unusually long tail of 22 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 13 years in total.
6 of the 9 agencies here assessed midazolam more than once, HAS (France) most often at 14 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for midazolam.
The full ledger for midazolam reads 22 recommended, 5 not recommended, 2 not assessed and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 2 Sep 2025 | Indication extension | SMR substantial · ASMR V | source |
| AOTMIT (Poland) | 31 Jul 2025 | Buccolam reimbursement recommendation | recommended | source |
| AWMSG (Wales) | 29 Jul 2024 | Treatment of prolonged, acute, convulsive seizures in adults, adolescents, children and infants aged 3 months and above | outside AWMSG criteria | source |
| ZIN (Netherlands) | 7 Jun 2024 | Advies - vergoed nasaal midazolam (Nasolam®) voor de behandeling van epilepsie | reimbursed | source |
| CIPM (Spain) | 12 Nov 2020 | Indicación terapéutica: OZALIN® está indicado en niños de 6 meses a 17 años de edad para la sedación moderada antes de u… | not financed by the SNS (financed 2025-07) | source |
25 further decisions for midazolam, across 8 agencies, are not shown here. They link to 17 further source documents.
Related molecules
- melatonin — same ATC class N05C — Psycholeptics
- dexmedetomidine — same ATC class N05C — Psycholeptics
- daridorexant — same ATC class N05C — Psycholeptics
- remimazolam — same ATC class N05C — Psycholeptics
- zolpidem — same ATC class N05C — Psycholeptics
- dydrogesterone — also decided by HAS in 2025Q3
Coverage: 30 decisions for midazolam from 9 agencies, 2003 to 2025. Data to 7 Sep 2026. ATC class N05C — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.